@article{3078063,
    title = "Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis",
    author = "Zinzani, P.L. and Chen, R. and Armand, P. and Johnson, N.A. and Brice, P. and Radford, J. and Ribrag, V. and Molin, D. and Vassilakopoulos, T.P. and Tomita, A. and von Tresckow, B. and Shipp, M.A. and Lin, J. and Nahar, A. and Balakumaran, A. and Moskowitz, C.H.",
    journal = "Clinical Lymphoma Myeloma and Leukemia",
    year = "2020",
    volume = "61",
    number = "4",
    pages = "950-954",
    publisher = "Taylor and Francis Ltd.",
    doi = "10.1080/10428194.2019.1702178",
    keywords = "brentuximab vedotin;  pembrolizumab;  antibody conjugate;  brentuximab vedotin;  monoclonal antibody;  pembrolizumab, adult;  adverse drug reaction;  allogeneic stem cell transplantation;  autologous stem cell transplantation;  bone marrow transplantation;  cancer regression;  cancer survival;  classical Hodgkin lymphoma;  clinical assessment;  clinical effectiveness;  clinical evaluation;  cohort analysis;  colitis;  cytokine release syndrome;  disease exacerbation;  drug efficacy;  drug safety;  drug withdrawal;  epilepsy;  female;  follow up;  graft versus host reaction;  human;  hyperthyroidism;  hypothyroidism;  incidence;  infusion related reaction;  iritis;  Letter;  leukemia relapse;  major clinical study;  male;  monotherapy;  myocarditis;  myositis;  overall survival;  pneumonia;  priority journal;  progression free survival;  salvage therapy;  sarcoidosis;  treatment duration;  treatment response;  treatment response time;  treatment withdrawal;  autotransplantation;  hematopoietic stem cell transplantation;  Hodgkin disease;  stem cell transplantation;  tumor recurrence, Antibodies, Monoclonal, Humanized;  Brentuximab Vedotin;  Hematopoietic Stem Cell Transplantation;  Hodgkin Disease;  Humans;  Immunoconjugates;  Neoplasm Recurrence, Local;  Salvage Therapy;  Stem Cell Transplantation;  Transplantation, Autologous"
}